1. New indolizidine- and pyrrolidine-type alkaloids with anti-angiogenic activities from Anisodus tanguticus
   Huan Zhu et al, 2023, Biomedicine & Pharmacotherapy CrossRef
2. miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf
   Hongxia Fu et al, 2018, Molecular Medicine Reports CrossRef
3. Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy
   Anand Maurya et al, 2022, Medulloblastoma CrossRef
4. Biologically active indolizidine alkaloids
   Junmin Zhang et al, 2021, Medicinal Research Reviews CrossRef
5. Improving the Oral Bioavailability of an Anti-Glioma Prodrug CAT3 Using Novel Solid Lipid Nanoparticles Containing Oleic Acid-CAT3 Conjugates
   Hongliang Wang et al, 2020, Pharmaceutics CrossRef
6. A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma
   Ru-Bing Wang et al, 2018, RSC Advances CrossRef
7. Improved Safety and Anti-Glioblastoma Efficacy of CAT3-Encapsulated SMEDDS through Metabolism Modification
   Hongliang Wang et al, 2021, Molecules CrossRef
8. Drug-like properties of serial phenanthroindolizidine alkaloid compounds: ADMET characteristic prediction and validation
   Hongliang Wang et al, 2024, Acta Materia Medica CrossRef
9. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway
   Ju Chen et al, 2016, Cancer Letters CrossRef